First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor

Advances in Therapy

Volumn 28, Issue 4, 2011, Pages 304-310

  Lefrère, François ^a   Brignier, Anne Colette ^a   Elie, Caroline ^b   Ribeil, Jean Antoine ^a   Bernimoulin, Michael ^a   Aoun, Charbel ^a   Dal Cortivo, Liliane ^a   Delarue, Richard ^a   Hermine, Olivier ^a   Cavazzana Calvo, Marina ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Autologous transplantation; Biosimilars; G CSF; Hematological malignancies; Leukapheresis; Stem cell mobilization; Zarzio

Indexed keywords

BORTEZOMIB; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE PAIN; CD34 SELECTION; CELL ISOLATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; HEADACHE; HUMAN; LEUKAPHERESIS; LYMPHOMA; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKAPHERESIS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RESEARCH DESIGN; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79958217024     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0009-1     Document Type: Article

References (25)

1. Child JA, Morgan GJ, Davies FE, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883. (Pubitemid 36532313)
2. Pettengell R, Radford JA, Morgenstern GR, et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol. 1996;14:586-592.
3. Lefrere F, Makke J, Fermand J, et al. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma. Bone Marrow Transplant. 1999;24:463-466. (Pubitemid 29423623)
4. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170.
5. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205. (Pubitemid 46638957)
6. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411-419. (Pubitemid 351325660)
7. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer. 2008;8:332.
8. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma. 2009;50:374-379.
9. Engert A, del Giglio A, Bias P, Lubenau H, Gatzemeier U, Heigener D. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie. 2009;32:599-604.
10. Gatzemeier U, Ciuleanu T, Dediu M, Ganea- Motan E, Lubenau H, Del Giglio A. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinumbased chemotherapy. J Thorac Oncol. 2009;4:736-740.
11. Gascon P, Fuhr U, Sörgel F, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010;21:1419-1429.
12. Lubenau H, Sveikata A, Gumbrevicius G, et al. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther. 2009;47:275-282.
13. Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs. 2009;23:43-51.
14. Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89:927-933.
15. Sörgel F, Lerch H, Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs. 2010;24:347-357.
16. Skrlin A, Radic I, Vuletic M, et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals. 2010;38:557-566.
17. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2010. Available at: http://www.r-project. org. Accessed March 4, 2011.
18. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:57-65.
19. Niitsu N. Current treatment strategy of diffuse large B-cell lymphomas. Int J Hematol. 2010;92:231-237.
20. Lefrère F, Zohar S, Ghez D, et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than highdose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplant. 2006;37:725-729.
21. Lefrère F, Bernard M, Audat F, et al. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell collection: a retrospective study of 126 patients. Leuk Lymphoma. 1999;35:501-505. (Pubitemid 30015649)
22. Perry AR, Watts MJ, Peniket AJ, Goldstone AH, Linch DC. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant. 1998;21:1201-1205. (Pubitemid 28318746)
23. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547-2555.
24. Engelhardt M, Bertz H, Afting M, Waller CF, Finke J. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol. 1999;17:2160-2172. (Pubitemid 29318849)
25. Vidal. Tarex 2011. Vidal, Issy Les Moulineaux, France, 2011. Available at: http://www.vidal.fr/lesproduits-professionnels/tarex. Accessed March 4, 2011.